Acute Myocardial Infarction (AMI)BRIDGENCT07741396
BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation
A study testing CBCR and BRIDGE mHealth intervention in people with Acute Myocardial Infarction (AMI) and Percutaneous Coronary Intervention (PCI), run by University of Illinois Chicago.
Trial summary
The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy lifestyle behaviors, better manage cardiovascular risk factors, and improve overall… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft Surgery (CABG)
- What is being tested?
- CBCR and BRIDGE mHealth intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 30 Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older.
- Enrolled in or referred to Phase II Center-based Cardiac Rehabilitation Program.
- Have a qualifying cardiovascular diagnosis or event that meets standard eligibility for Phase II Center-based Cardiac Rehabilitation, such as:
- Acute myocardial infarction
- Percutaneous coronary intervention
- Coronary artery bypass graft surgery
Show all 13Show fewer
- Chronic heart failure with reduced ejection fraction
- Heart valve repair or replacement
- Stable angina
- Able to ambulate and participate in exercise testing and training as required by the CR program
- Ability to speak and read in English
- Willing and able to provide informed consent.
- Willing to use study-related devices/apps and complete study assessments.
Who cannot join
- Not enrolled in or not planning to participate in Phase II Center-based Cardiac Rehabilitation Program.
- Presence of a medical, cognitive, psychiatric, or physical condition that, in the opinion of the investigators or CR team, would preclude safe participation in the study or adherence to study procedures.
- Severe cognitive impairment or active psychiatric illness that would interfere with informed consent or study participation.
- Terminal illness or other serious medical condition that in the judgement of the treating clinician or investigator would likely preclude completion of the study follow-up period. .
- Current hospice enrollment or residence in a long-term care facility that would preclude participation in the intervention or completion of study follow-up procedures.
- Currently participating in another behavioral or digital health intervention trial that could confound study outcomes.
- Inability or unwillingness to use the required mobile devices, applications, or monitoring equipment, if applicable.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation as a Model for Chronic Disease Management
The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy lifestyle behaviors, better manage cardiovascular risk factors, and improve overall health outcomes.
Cardiac rehabilitation is an evidence-based outpatient program designed to help people recover from heart-related conditions through supervised exercise, education, counseling, and support for healthy lifestyle changes. Although cardiac rehabilitation is highly recommended and beneficial, many patients do not receive the full benefits of the program. Some patients attend fewer sessions than recommended, and many find it difficult to maintain healthy habits outside of the clinic, such as regular physical activity, heart-healthy eating, taking medications as prescribed, monitoring blood pressure, and managing weight.
Read more
This study will test whether combining CBCR with mobile health tools may improve participation and support healthy behaviors at home. Mobile health tools include mobile phone applications, connected devices such as a weight scale, blood pressure monitor, and activity tracker, as well as personalized text messages designed to encourage and support healthy self-care.
This study will help determine whether these mobile health tools can make cardiac rehabilitation more effective and help patients maintain healthy behaviors beyond the clinic setting.
Read the detailed description
Phase II Cardiac Rehabilitation (CR) is an evidence-based secondary prevention program for patients with cardiovascular disease (CVD).The core components of comprehensive CR are well-established and include patient assessment, exercise training, physical activity (PA) promotion, health education, nutritional counseling, psychological support, and CVD risk management. Phase II CR programs generally offer three sessions per week in an outpatient center - known as center-based CR (CBCR) - and supplemental healthy lifestyle behaviors are encouraged in patients' daily living environments. Despite strong evidence supporting the effectiveness of CBCR, its impact is constrained by four main barriers: 1) patients often fail to maintain adequate physical activity on non-CR days; 2) many patients fail to attend all prescribed CR sessions while others prematurely discontinue the program; 3) many CBCR programs are exercise-centered, offering minimal attention to other core components (e.g. risk management); and 4) reach remains limited, with poor adherence to home-based recommendations. Data shows that up to 86.5% of CR participants fail to meet guideline-recommended weekly PA targets and remain largely inactive on non-CR days. Also, only 26.9% of participants completed the 36-session course of CBCR, while 56.7% attended at least 25 sessions - a threshold associated with significant health benefits. Additionally, standardized educational programs for CR participants are lacking across many healthcare systems, and it is reported that a lack of CR knowledge and low self-efficacy are significant barriers to CR adherence and PA regimen adherence. Many CR programs do not fully deliver all components of comprehensive CR, with a tendency to emphasize exercise training while providing less consistent attention to diet, medication adherence, and other risk management components. Innovative and scalable strategies that extend patient support beyond the clinic and reinforce behavior change are urgently needed to maximize the clinical benefits of CBCR.
Mobile health (mHealth) technologies, such as smartphones, apps, text messages, wearables, and other commercially available connected health devices, have gained popularity in recent years. These mHealth tools offer a promising adjunctive approach to traditional CBCR programs, helping overcome some of the existing challenges. Mobile apps and wearable activity trackers can facilitate more frequent self-monitoring in the community and encourage positive health behaviors, including self-management of CVD. Evidence shows that text messages (TMs) are associated with improvements in PA and medication adherence among different populations and support self-management of chronic conditions. Our recent systematic review published in The Lancet Digital Health demonstrates that provision of exercise-based CR at home facilitated by mHealth technologies is associated with significantly greater benefits in functional capacity and other health outcomes compared with usual care. These findings confirmed that mHealth can effectively enable patients to engage in CR-related behaviors outside formal outpatient settings. However, very few studies have evaluated mHealth as an adjunct to CBCR to extend behavioral support in people's daily living environments. The question of whether mHealth tools can meaningfully augment the effectiveness of CBCR remains largely underexplored. Additionally, prior studies have mainly tested research-developed apps that are not commercially available, thus limiting scalability and potential for real-world implementation. The effect of tailored theory-based TM programs combined with widely used commercial mHealth tools among CBCR participants remains underexplored.
To address these gaps, our study team has developed an mHealth intervention (BRIDGE) that integrates commercially available mHealth apps (Fitbit app and Withings app) and connected devices (Fitbit tracker, Withings BP and weight monitor) with individually tailored TMs selected from a study-developed TM library. BRIDGE intervention will augment CBCR by targeting multiple CR components, including exercise training, PA, heart-healthy diet, weight management, and CVD risk management.
The goal of the proposed project is to evaluate the feasibility, acceptability, and preliminary efficacy of the BRIDGE intervention in improving exercise capacity and self-reported health outcomes through a randomized controlled trial (RCT). A total of 30 CR participants will be recruited and randomized to one of two treatment groups: (1) CBCR alone, (2) CBCR + BRIDGE intervention.
- Conditions
- Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft Surgery (CABG), Chronic Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Valve Repair or Replacement, Stable Angina Pectoris
- Being tested
- CBCR, BRIDGE mHealth intervention
- Keywords
- cardiac rehabilitation, mHealth, digital tool, consumer-grade technology
- Medical subject headings
- Angina, Stable
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CBCROther
Also called Comprehensive CBCR
The CBCR program at UI Health is a structured, medically supervised secondary prevention program for patients with qualifying cardiovascular conditions. It includes individualized aerobic and resistance exercise training, clinical monitoring during exercise sessions, education on heart disease and risk factor management, counseling to promote healthy lifestyle behaviors, and support for long-term adherence to prescribed treatment and self-care recommendations. Participants are encouraged to attend up to 36 supervised sessions over ~12 weeks.
BRIDGE mHealth interventionBehavioural
Description: The intervention includes three commercially available mHealth apps and devices: Withings Body Composition weight scale, Withings BP monitor, and Fitbit Charge 6 activity tracker along with their companion mobile apps. Each app incorporates behavior change tools that support daily self-monitoring, feedback, and reminders across key cardiac rehabilitation domains, including physical activity, weight and blood pressure management, and cardiovascular risk factor reduction. Participants will also receive up to five individually tailored text messages per week throughout the intervention period. Messages will be individualized based on (1) patient responses to validated questionnaires administered at baseline and (2) patient-generated health data from the app/devices. Messages will target physical activity, healthy eating, weight management, blood pressure control, and cardiovascular risk reduction.
| Study group | Role | What they receive |
|---|---|---|
| CBCR only | Active comparator | Participants randomized to the control group will receive standard outpatient CBCR at UI Health with no additional study-delivered mHealth intervention. The CBCR program at UI Health is a structured, medically supervised secondary prevention program for patients with qualifying cardiovascular conditions. It includes individualized aerobic and resistance exercise training, clinical monitoring during exercise sessions, education on heart disease and risk factor management, counseling to promote healthy lifestyle behaviors, and support for long-term adherence to prescribed treatment and self-care recommendations.
Participants are encouraged to attend up to 36 supervised sessions over ~12 weeks. In addition to supervised exercise, CBCR includes education related to cardiovascular disease self-management, physical activity, healthy eating, weight management, lipid control, blood pressure management, smoking cessation, stress reduction, and other risk factor modification strtegies. Receives: Other: CBCR |
| CBCR + BRIDGE | Experimental | Participants randomized to the intervention group will receive BRIDGE in addition to the standard CBCR program at UI Health. BRIDGE is a multimodal mHealth intervention designed to extend behavioral support beyond clinic visits through mobile app- and device-based self-monitoring, feedback, and individually tailored text messages promoting healthy lifestyle behaviors (e.g. physical activity, heart healthy diet, and medication adherence). Receives: Other: CBCR; Behavioral: BRIDGE mHealth intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Functional capacity as measured by peak metabolic equivalents (METs).
Peak metabolic equivalents (METs) is a valid, clinically meaningful, and widely accepted measure of functional capacity in patients with CVD and in CR settings. It's found that peak functional capacity measured in METs is the strongest predictor of mortality risk in both normal subjects and patients with CVD. Each one MET increase is has been associated with 25% reduction in all-cause mortality among CR patients.
Peak METs will be generated by the clinic's telemetry system (cardiline) during graded exercise test (GXT), using workload estimates derived from treadmill speed and grade. Peak METs are routinely used in the CR clinic to guide individualized exercise prescription.
Measured: * Baseline; * End of the CBCR program, an average of 12 weeks
Secondary outcomes (5)
Blood pressure
Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) will be measured at the clinic and reported in the patient's chart (EMR).
Measured: * Baseline; * End of the CBCR program, an average of 12 weeks
Body Mass Index (BMI)
BMI will be used to measure weight management and body composition.
Measured: * Baseline; * End of the CBCR program, an average of 12 weeks
Depression as measured by the Patient Health Questionnaire-9 (PHQ-9)
Depression will be assessed by the Patient Health Questionnaire-9 (PHQ-9). PHQ-9 is a reliable and valid measure to screen and measure the level of depression. It has been extensively tested in various populations with excellent psychometric properties (Cronbach's α 0.86-0.89). The total score ranges from 0 to 27, with a higher score indicating a more severe level of depression.
Measured: * Baseline; * End of the CBCR program, an average of 12 weeks
Health related quality of life (HRQoL)
Health related quality of life (HRQoL) will be assessed with the Medical Outcomes 36-Item Short Survey (SF-36). SF-36 has been used extensively in CR studies, and its psychometric properties have been tested among patients with CVD. The 36 items are divided into 8 subscales: Physical Functioning, Roles Limitations due to Physical Problems, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, General Mental Health, and Health Transition. Items within each subscale are totaled to yield a summed score for that subscale. Each summed score ranges from 0 (negative health) to 100 (positive health).
Measured: * Baseline; * End of the CBCR program, an average of 12 weeks
CR completion rate
Percentage of completed CR sessions over the prescribed sessions at the end of the study.
Measured: * End of the CBCR program, an average of 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2026
- Study start1 Sep 2026 (estimated)
- Primary completion30 Mar 2027 (estimated)
- Study completion30 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Myocardial Infarction (AMI)Studies of the same condition, open and under way.
- More trials run by University of Illinois ChicagoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Illinois Chicago
- Sponsor type
- University, hospital or other
- Collaborators
- National Center for Advancing Translational Sciences (NCATS)
- Responsible party
- Sponsor
- Investigators
- Spyros Kitsiou, PhD, Principal investigator, University of Illinois Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07741396
- Sponsor's protocol ID
- STUDY2025-0931
- Acronym
- BRIDGE
- Status last verified
- Jun 2026
- First submitted
- 21 Jul 2026
- Last updated
- 3 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BRIDGE Trial: Embedding Consumer-grade mHealth Technologies Into Cardiac Rehabilitation as a Model for Chronic Disease Management
- ClinicalTrials.gov ID
- NCT07741396
- Acronym / sponsor ID
- BRIDGE / STUDY2025-0931
- Conditions
- Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft Surgery (CABG), Chronic Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Valve Repair or Replacement, Stable Angina Pectoris
- Keywords
- cardiac rehabilitation, mHealth, digital tool, consumer-grade technology
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University of Illinois ChicagoUniversity, hospital or other
- Collaborators
- National Center for Advancing Translational Sciences (NCATS)
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 30 Mar 2027 (estimated)
- Study completion
- 30 Jul 2027 (estimated)
- First posted
- 3 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the BRIDGE study is to learn whether supplementing traditional center-based cardiac rehabilitation (CBCR) with a mobile health technology intervention can help patients monitor their health, stay engaged in healthy lifestyle behaviors, better manage cardiovascular risk factors, and improve overall health outcomes.
Cardiac rehabilitation is an evidence-based outpatient program designed to help people recover from heart-related conditions through supervised exercise, education, counseling, and support for healthy lifestyle changes. Although cardiac rehabilitation is highly recommended and beneficial, many patients do not receive the full benefits of the program. Some patients attend fewer sessions than recommended, and many find it difficult to maintain healthy habits outside of the clinic, such as regular physical activity, heart-healthy eating, taking medications as prescribed, monitoring blood pressure, and managing weight.
This study will test whether combining CBCR with mobile health tools may improve participation and support healthy behaviors at home. Mobile health tools include mobile phone applications, connected devices such as a weight scale, blood pressure monitor, and activity tracker, as well as personalized text messages designed to encourage and support healthy self-care.
This study will help determine whether these mobile health tools can make cardiac rehabilitation more effective and help patients maintain healthy behaviors beyond the clinic setting.
Detailed description
Phase II Cardiac Rehabilitation (CR) is an evidence-based secondary prevention program for patients with cardiovascular disease (CVD).The core components of comprehensive CR are well-established and include patient assessment, exercise training, physical activity (PA) promotion, health education, nutritional counseling, psychological support, and CVD risk management. Phase II CR programs generally offer three sessions per week in an outpatient center - known as center-based CR (CBCR) - and supplemental healthy lifestyle behaviors are encouraged in patients' daily living environments. Despite strong evidence supporting the effectiveness of CBCR, its impact is constrained by four main barriers: 1) patients often fail to maintain adequate physical activity on non-CR days; 2) many patients fail to attend all prescribed CR sessions while others prematurely discontinue the program; 3) many CBCR programs are exercise-centered, offering minimal attention to other core components (e.g. risk management); and 4) reach remains limited, with poor adherence to home-based recommendations. Data shows that up to 86.5% of CR participants fail to meet guideline-recommended weekly PA targets and remain largely inactive on non-CR days. Also, only 26.9% of participants completed the 36-session course of CBCR, while 56.7% attended at least 25 sessions - a threshold associated with significant health benefits. Additionally, standardized educational programs for CR participants are lacking across many healthcare systems, and it is reported that a lack of CR knowledge and low self-efficacy are significant barriers to CR adherence and PA regimen adherence. Many CR programs do not fully deliver all components of comprehensive CR, with a tendency to emphasize exercise training while providing less consistent attention to diet, medication adherence, and other risk management components. Innovative and scalable strategies that extend patient support beyond the clinic and reinforce behavior change are urgently needed to maximize the clinical benefits of CBCR.
Mobile health (mHealth) technologies, such as smartphones, apps, text messages, wearables, and other commercially available connected health devices, have gained popularity in recent years. These mHealth tools offer a promising adjunctive approach to traditional CBCR programs, helping overcome some of the existing challenges. Mobile apps and wearable activity trackers can facilitate more frequent self-monitoring in the community and encourage positive health behaviors, including self-management of CVD. Evidence shows that text messages (TMs) are associated with improvements in PA and medication adherence among different populations and support self-management of chronic conditions. Our recent systematic review published in The Lancet Digital Health demonstrates that provision of exercise-based CR at home facilitated by mHealth technologies is associated with significantly greater benefits in functional capacity and other health outcomes compared with usual care. These findings confirmed that mHealth can effectively enable patients to engage in CR-related behaviors outside formal outpatient settings. However, very few studies have evaluated mHealth as an adjunct to CBCR to extend behavioral support in people's daily living environments. The question of whether mHealth tools can meaningfully augment the effectiveness of CBCR remains largely underexplored. Additionally, prior studies have mainly tested research-developed apps that are not commercially available, thus limiting scalability and potential for real-world implementation. The effect of tailored theory-based TM programs combined with widely used commercial mHealth tools among CBCR participants remains underexplored.
To address these gaps, our study team has developed an mHealth intervention (BRIDGE) that integrates commercially available mHealth apps (Fitbit app and Withings app) and connected devices (Fitbit tracker, Withings BP and weight monitor) with individually tailored TMs selected from a study-developed TM library. BRIDGE intervention will augment CBCR by targeting multiple CR components, including exercise training, PA, heart-healthy diet, weight management, and CVD risk management.
The goal of the proposed project is to evaluate the feasibility, acceptability, and preliminary efficacy of the BRIDGE intervention in improving exercise capacity and self-reported health outcomes through a randomized controlled trial (RCT). A total of 30 CR participants will be recruited and randomized to one of two treatment groups: (1) CBCR alone, (2) CBCR + BRIDGE intervention.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CBCR only | Active comparator | Other: CBCRParticipants randomized to the control group will receive standard outpatient CBCR at UI Health with no additional study-delivered mHealth intervention. The CBCR program at UI Health is a structured, medically supervised secondary prevention program for patients with qualifying cardiovascular conditions. It includes individualized aerobic and resistance exercise training, clinical monitoring during exercise sessions, education on heart disease and risk factor management, counseling to promote healthy lifestyle behaviors, and support for long-term adherence to prescribed treatment and self-care recommendations. Participants are encouraged to attend up to 36 supervised sessions over ~12 weeks. In addition to supervised exercise, CBCR includes education related to cardiovascular disease self-management, physical activity, healthy eating, weight management, lipid control, blood pressure management, smoking cessation, stress reduction, and other risk factor modification strtegies. |
| CBCR + BRIDGE | Experimental | Other: CBCR, Behavioral: BRIDGE mHealth interventionParticipants randomized to the intervention group will receive BRIDGE in addition to the standard CBCR program at UI Health. BRIDGE is a multimodal mHealth intervention designed to extend behavioral support beyond clinic visits through mobile app- and device-based self-monitoring, feedback, and individually tailored text messages promoting healthy lifestyle behaviors (e.g. physical activity, heart healthy diet, and medication adherence). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Adults aged 18 years or older.
- Enrolled in or referred to Phase II Center-based Cardiac Rehabilitation Program.
- Have a qualifying cardiovascular diagnosis or event that meets standard eligibility for Phase II Center-based Cardiac Rehabilitation, such as:
- Able to ambulate and participate in exercise testing and training as required by the CR program
- Ability to speak and read in English
Key exclusion criteria (7 listed)
- Not enrolled in or not planning to participate in Phase II Center-based Cardiac Rehabilitation Program.
- Presence of a medical, cognitive, psychiatric, or physical condition that, in the opinion of the investigators or CR team, would preclude safe participation in the study or adherence to study procedures.
- Severe cognitive impairment or active psychiatric illness that would interfere with informed consent or study participation.
- Terminal illness or other serious medical condition that in the judgement of the treating clinician or investigator would likely preclude completion of the study follow-up period. .
- Current hospice enrollment or residence in a long-term care facility that would preclude participation in the intervention or completion of study follow-up procedures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CBCRAlso: Comprehensive CBCRThe CBCR program at UI Health is a structured, medically supervised secondary prevention program for patients with qualifying cardiovascular conditions. It includes individualized aerobic and resistance exercise training, clinical monitoring during exercise sessions, education on heart disease and risk factor management, counseling to promote healthy lifestyle behaviors, and support for long-term adherence to prescribed treatment and self-care recommendations. Participants are encouraged to attend up to 36 supervised sessions over ~12 weeks. | Other | CBCR + BRIDGE, CBCR only |
| BRIDGE mHealth interventionDescription: The intervention includes three commercially available mHealth apps and devices: Withings Body Composition weight scale, Withings BP monitor, and Fitbit Charge 6 activity tracker along with their companion mobile apps. Each app incorporates behavior change tools that support daily self-monitoring, feedback, and reminders across key cardiac rehabilitation domains, including physical activity, weight and blood pressure management, and cardiovascular risk factor reduction. Participants will also receive up to five individually tailored text messages per week throughout the intervention period. Messages will be individualized based on (1) patient responses to validated questionnaires administered at baseline and (2) patient-generated health data from the app/devices. Messages will target physical activity, healthy eating, weight management, blood pressure control, and cardiovascular risk reduction. | Behavioural | CBCR + BRIDGE |
Primary outcome
Functional capacity as measured by peak metabolic equivalents (METs).
Time frame: * Baseline; * End of the CBCR program, an average of 12 weeks
Peak metabolic equivalents (METs) is a valid, clinically meaningful, and widely accepted measure of functional capacity in patients with CVD and in CR settings. It's found that peak functional capacity measured in METs is the strongest predictor of mortality risk in both normal subjects and patients with CVD. Each one MET increase is has been associated with 25% reduction in all-cause mortality among CR patients. Peak METs will be generated by the clinic's telemetry system (cardiline) during graded exercise test (GXT), using workload estimates derived from treadmill speed and grade. Peak METs are routinely used in the CR clinic to guide individualized exercise prescription.
5 secondary outcomes
Blood pressure
Time frame: * Baseline; * End of the CBCR program, an average of 12 weeks
Body Mass Index (BMI)
Time frame: * Baseline; * End of the CBCR program, an average of 12 weeks
Depression as measured by the Patient Health Questionnaire-9 (PHQ-9)
Time frame: * Baseline; * End of the CBCR program, an average of 12 weeks
Health related quality of life (HRQoL)
Time frame: * Baseline; * End of the CBCR program, an average of 12 weeks
CR completion rate
Time frame: * End of the CBCR program, an average of 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Myocardial Infarction (AMI)
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Spyros Kitsiou, PhD principal investigator
University of Illinois Chicago
Questions about this trial
What is this clinical trial studying?
A study testing CBCR and BRIDGE mHealth intervention in people with Acute Myocardial Infarction (AMI) and Percutaneous Coronary Intervention (PCI), run by University of Illinois Chicago.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Leah Li, MSN, RN (13123553519, yli351@uic.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Functional capacity as measured by peak metabolic equivalents (METs). (time frame: * Baseline; * End of the CBCR program, an average of 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026.